161659-80-9

Usage

Uses

Used in Pharmaceutical Industry:
(S)-1-N-Benzyl-beta-proline is used as a pharmaceutical intermediate for the synthesis of various drugs. Its chiral nature and diverse biological activities make it a valuable compound in the development of novel therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical industry, (S)-1-N-Benzyl-beta-proline is used as a building block for the synthesis of agrochemicals with potential applications in pest control and crop protection. Its antibacterial and antiviral properties contribute to the development of effective and environmentally friendly agrochemicals.
Used in Materials Science:
(S)-1-N-Benzyl-beta-proline is utilized in materials science for the development of novel materials with unique properties. The benzyl group attached to the proline molecule can be manipulated to create materials with specific characteristics, such as improved stability or enhanced biological activity.
Used in Research and Development:
(S)-1-N-Benzyl-beta-proline serves as a key compound in research and development efforts aimed at discovering new compounds with potential applications in medicine and other industries. Its chiral nature and diverse biological activities make it an attractive candidate for further exploration and innovation.

InChI:InChI=1/C12H15NO2/c14-12(15)11-6-7-13(9-11)8-10-4-2-1-3-5-10/h1-5,11H,6-9H2,(H,14,15)/t11-/m0/s1

Upstream product

• 159063-16-8 (S)-1-benzylpyrrolidine-3-carbonitrile 
• 114715-35-4 (R)-3-methanesulfonyloxy-1-(phenylmethyl)-pyrrolidine 
• 72580-53-1 (S)-(+)-3-pyrrolidinecarboxylic acid 
• 101385-90-4 (R)-N-benzyl-3-hydroxypyrrolidine 
• 100-52-7 benzaldehyde 

Downstream Products

• 72580-53-1 (S)-(+)-3-pyrrolidinecarboxylic acid 
• 218431-61-9 (S)-1-Benzyl-pyrrolidine-3-carboxylic acid [(S)-1-(carbamoylmethyl-carbamoyl)-3-methyl-butyl]-amide 
• 218431-60-8 {(S)-2-[((S)-1-Benzyl-pyrrolidine-3-carbonyl)-amino]-4-methyl-pentanoylamino}-acetic acid ethyl ester 

Relevant academic research and scientific papers

Discovery of novel n-substituted prolinamido indazoles as potent rho kinase inhibitors and vasorelaxation agents

Inhibitors of Rho kinase (ROCK) have potential therapeutic applicability in a wide range of diseases, such as hypertension, stroke, asthma and glaucoma. In a previous article, we described the lead discovery of DL0805, a new ROCK I inhibitor, showing potent inhibitory activity (IC50 6.7 μM). Herein, we present the lead optimization of compound DL0805, resulting in the discovery of 24- and 39-fold more-active analogues 4a (IC50 0.27 μM) and 4b (IC50 0.17 μM), among other active analogues. Moreover, ex-vivo studies demonstrated that 4a and 4b exhibited comparable vasorelaxant activity to the approved drug fasudil in rat aortic rings. The research of a preliminary structure-activity relationship (SAR) indicated that the target compounds containing a β-proline moiety have improved activity against ROCK I relative to analogues bearing an β-proline moiety, and among the series of the derivatives with a β-proline-derived indazole scaffold, the inhibitory activity of the target compounds with a benzyl substituent is superior to those with a benzoyl substituent.

2-Dibenzylaminobutane-1,4-diol: A Versatile Intermediate for a Chirospecific β-amino Acid Synthesis

Starting from the chiral building block 1, which is readily available from natural aspartic acid, a concise and versatile synthesis of optically active β-amino acids including β-proline derivatives is reported.Regioselective transformations of the 1,4-bis-electrophile 2 are facilitated by an anchimeric participation.